128 related articles for article (PubMed ID: 24526734)
1. Molecular biomarkers in advanced renal cell carcinoma.
Maroto P; Rini B
Clin Cancer Res; 2014 Apr; 20(8):2060-71. PubMed ID: 24526734
[TBL] [Abstract][Full Text] [Related]
2. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM
Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
Tang PA; Vickers MM; Heng DY
Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma.
Funakoshi T; Lee CH; Hsieh JJ
Cancer Treat Rev; 2014 May; 40(4):533-47. PubMed ID: 24398141
[TBL] [Abstract][Full Text] [Related]
5. Precision medicine for metastatic renal cell carcinoma.
Sonpavde G; Choueiri TK
Urol Oncol; 2014 Jan; 32(1):5-15. PubMed ID: 24239472
[TBL] [Abstract][Full Text] [Related]
6. [Biomarkers of response to molecular targeted therapy in renal cell carcinoma].
Mizuno R; Oya M
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1088-91. PubMed ID: 21772092
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Albiges L; Salem M; Rini B; Escudier B
Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
[TBL] [Abstract][Full Text] [Related]
8. The role of pharmacogenomics in metastatic renal cell carcinoma.
Castellano D; Virizuela JA; Cruz J; Sepulveda JM; Sáez MI; Paz-Ares L
Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S29-32. PubMed ID: 22723081
[TBL] [Abstract][Full Text] [Related]
9. Prognostic biomarkers in renal cell carcinoma.
Jiang Z
Expert Rev Mol Diagn; 2007 May; 7(3):293-307. PubMed ID: 17489736
[TBL] [Abstract][Full Text] [Related]
10. Predictors of response to targeted therapy in renal cell carcinoma.
Eisengart LJ; MacVicar GR; Yang XJ
Arch Pathol Lab Med; 2012 May; 136(5):490-5. PubMed ID: 22229848
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.
Vano YA; Tartour E; Fournier LS; Beuselinck B; Mejean A; Oudard S
Expert Rev Anticancer Ther; 2014 May; 14(5):523-42. PubMed ID: 24640949
[TBL] [Abstract][Full Text] [Related]
12. Renal cell carcinoma: resistance to therapy, role of apoptosis, and the prognostic and therapeutic target potential of TRAF proteins.
Rajandram R; Bennett NC; Morais C; Johnson DW; Gobe GC
Med Hypotheses; 2012 Feb; 78(2):330-6. PubMed ID: 22153576
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor as a biomarker for endostatin gene therapy.
Braga MS; Turaça TL; Foguer K; Chaves KC; Pesquero JB; Chammas R; Schor N; Bellini MH
Biomed Pharmacother; 2013 Jul; 67(6):511-5. PubMed ID: 23726969
[TBL] [Abstract][Full Text] [Related]
14. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.
Mulders P
BJU Int; 2009 Dec; 104(11):1585-9. PubMed ID: 20053190
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
17. Successes and limitations of targeted therapies in renal cell carcinoma.
Pracht M; Berthold D
Prog Tumor Res; 2014; 41():98-112. PubMed ID: 24727990
[TBL] [Abstract][Full Text] [Related]
18. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
[TBL] [Abstract][Full Text] [Related]
19. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
Ljungberg BJ; Jacobsen J; Rudolfsson SH; Lindh G; Grankvist K; Rasmuson T
BJU Int; 2006 Sep; 98(3):661-7. PubMed ID: 16925769
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers in clear cell renal cell carcinoma.
George S; Bukowski RM
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1737-47. PubMed ID: 18062748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
